Physician profile
Sonia Singh
NPI 1013357409
$2,518.00
in general payments reported to CMS, 2019-2025
35 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $436 · 2023: $518 · 2024: $775 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.48 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $322.71 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Seagen INC. | $263.96 | 2021-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $230.97 | 2021-2025 | |
| Daiichi Sankyo INC. | $228.04 | 2021-2025 | Injectafer, Enhertu, Vanflyta |
| Emd Serono, INC. | $125.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $110.48 | 2022-2024 | Enhertu |
| Celgene Corporation | $98.92 | 2021-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $93.72 | 2024 | Hyqvia, Vpriv, Ninlaro |
| Puma Biotechnology, INC. | $89.44 | 2023-2025 | Nerlynx |
| Janssen Scientific Affairs, LLC | $86.84 | 2024-2025 | Rybrevant |
| Pfizer INC. | $79.01 | 2022-2024 | |
| Kyowa Kirin, INC. | $63.71 | 2024-2025 | Poteligeo |
| Coherus Oncology, INC. | $59.41 | 2022-2023 | |
| Organon LLC | $49.21 | 2022 | |
| Genzyme Corporation | $48.70 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $47.60 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.72 | 2024-2025 | Lynparza, Keytruda |
| Karyopharm Therapeutics INC. | $39.30 | 2022-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $38.06 | 2024 | |
| Abbvie INC. | $37.98 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $37.47 | 2021-2022 | |
| Genentech USA, INC. | $37.27 | 2024-2025 | Phesgo |
| Taiho Oncology, INC. | $36.44 | 2024-2025 | |
| Lilly USA, LLC | $32.26 | 2024 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $31.70 | 2021-2024 | Ultomiris |
| Incyte Corporation | $28.09 | 2024 | Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $25.60 | 2023 | Jemperli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2021 | |
| Sobi, INC | $18.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.03 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.67 | 2023 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $14.50 | 2021 | |
| Dova Pharmaceuticals | $13.45 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.